This white paper focuses on a new generation of single-use bioreactors, built to deliver high-volume performance and how they address many issue.
Eisbach Bio GmbH is a spin-off of the Ludwig Maximilian University in Munich. The company is located in the Innovation and Start-up Centre IZB in Planegg-Martinsried.
Abstract: This white paper explores how to leverage hot melt extrusion solutions for small molecules.
James Brook, since June 2021 Head of Europe, Africa and Middle-East at Tigermed, about clinical research, and plans for his new role.
Beijing, China October 19, 2021 – Sino Biological, Inc. (Sino Biological or the Company), a biotechnology company which provides biological research reagents and related technical contract research services, will be featured on Worldwide Business with kathy ireland®, airing on FOX Business Network, Bloomberg International and other outlets as sponsored content. Hosted by business mogul Kathy Ireland, this award-winning television series takes an in-depth look at companies around the world currently impacting different sectors of business and society. Dr. Rob Burgess, Chief Business Officer for Sino Biological, will be interviewed.
The Whos Who of the biotech industry relies on Austria. Every second biotechnology company is located in the hotspot of Vienna, where a leading research centre the Campus Vienna BioCenter has emerged. Multinationals and startups benefit from an extensive value chain, from basic research to production and distribution. The national investment promotion agency Austrian Business Agency (ABA) is the first point of contact when making the leap into the Austrian market.
Richter-Helm is a leading and expanding Germany-based contract development and manufacturing organization (CDMO). Richter-Helm provides excellent services in the continuously growing market of pharmaceutical biotechnology. Offering a broad range of microbial manufacturing, development and analytical services, Richter-Helm will bring customer projects to the next level.
The success of any adoptive cell therapy lies in how effectively and selectively engineered immune cells interact and kill cancer cells. Functional phenomics enables insights that can dramatically accelerate the development of next-gen cell therapies. evorion biotechnologies brings functional phenomics to pharma and biotech partners via exclusive access to a unique, proprietary pipeline for in-depth multi-modal analysis of thousands of cell-cell interactions at single-cell resolution.
This whitepaper provides insights into why it is critical to manage, optimize and streamline a supply chain to mitigate risks, such as those brought on by the COVID-19 pandemic.
Small-volume biopharmaceutical processes continue to grow as more biopharmaceutical, cell therapy and gene therapy companies develop products. A 2021 Association for Regenerative Medicine (ARM) report states that there are 1,085 cell, gene and tissue-based therapy developers worldwide. These companies are engaged in many small-volume (<10L) processes including early-stage drug development and autologous therapies.